Weight often returns once you stop the medication
A new chapter in the long human struggle with weight and appetite has quietly opened on British high streets: the first approved oral version of semaglutide, the active ingredient in Wegovy, is now available privately at UK pharmacies. Where once only a weekly injection offered this pharmaceutical pathway, a daily pill now extends the choice — though not without its own discipline and cost. The treatment reflects both the promise of modern pharmacology and the enduring complexity of obesity, a condition shaped as much by environment and habit as by biology.
- The pill form of Wegovy removes the needle barrier for many, but replaces it with a demanding daily ritual — empty stomach, strict fasting, plain water only — that may suit some patients less than the injection it mirrors.
- Clinical trials show the tablet achieves comparable weight loss to the injection, with participants losing over 13% of body weight on average versus just over 2% on placebo, lending the new format genuine medical credibility.
- Priced between £99 and £199 per month depending on dose, the pill remains a private expense with NHS access contingent on a NICE cost-effectiveness review that has yet to conclude.
- Health experts are sounding a clear warning: these medications are not cosmetic shortcuts, and the weight typically returns when treatment stops, making sustained lifestyle change an essential companion to any pharmaceutical intervention.
- The structural roots of obesity — cheap, abundant, heavily marketed food at every turn — remain untouched by the pill's approval, a tension that researchers like Oxford's Susan Jebb argue no drug alone can resolve.
For anyone who has recoiled from the idea of a weekly injection, the arrival of an oral version of Wegovy at UK pharmacies marks a meaningful shift. The pill contains the same active ingredient — semaglutide — and clinical evidence suggests it performs comparably to the injection. But it carries its own demands: taken daily on an empty stomach after at least eight hours of fasting, swallowed with no more than a small glass of plain water, and followed by a 30-minute window before eating, drinking, or taking other medications.
Eligibility follows the same criteria as the injection — a BMI of 30 or above, or between 27 and 30 with a weight-related condition such as type 2 diabetes or high blood pressure. Doses begin at 1.5 milligrams and rise monthly to a maximum of 25 milligrams, with prices ranging from £99 to £199 per month. In a 64-week trial, participants lost an average of 13.61% of their body weight compared to 2.18% on placebo. Side effects are predominantly gastrointestinal, though rarer complications including pancreatitis and severe allergic reactions are possible.
Health experts are emphatic that these treatments are not quick cosmetic fixes. Weight typically returns after stopping, and the medication is intended as a long-term tool alongside genuine lifestyle change. Professor Susan Jebb of Oxford points to the deeper problem: an environment saturated with cheap, tempting food that quietly undermines even the best intentions.
The pill received regulatory approval from the MHRA earlier this month — the first oral treatment of its kind cleared in the UK — but NHS access awaits a separate NICE review of cost-effectiveness. For now, it remains a private option, available to those who can afford it and willing to meet the strict conditions that come with choosing a tablet over a syringe.
For anyone who has winced at the thought of a weekly injection but wanted access to semaglutide, the calculus just shifted. The pill version of Wegovy—the weight-loss treatment that has become shorthand for pharmaceutical intervention in obesity—is now available to buy privately across UK pharmacies, both online and on the high street. It contains the same active ingredient as the injection, semaglutide, and clinical trials suggest it works just as well. But the pill comes with its own set of demands, and the path to NHS availability remains uncertain.
The choice between pill and injection hinges on lifestyle and tolerance. Both are similarly effective, but they require different commitments. The injection goes under the skin once a week and can be taken at any time of day, though it must be refrigerated. The pill, by contrast, demands a daily ritual with strict rules: an empty stomach after at least eight hours of fasting, swallowed whole with no more than 120 millilitres of plain water, and then a 30-minute wait before eating or drinking anything else or taking other medications. For some, the needle is the dealbreaker. For others, the daily discipline and the fasting window make the injection the more practical choice.
Eligibility mirrors the injection criteria. You need a BMI of 30 or above—the clinical threshold for obesity—or a BMI between 27 and 30 if you also have weight-related health conditions like type 2 diabetes or high blood pressure. A consultation, online or in person, is required before you can start. The starting dose is 1.5 milligrams once daily for a month, then the dose typically increases each month until reaching the maximum of 25 milligrams. Some pharmacies are currently pricing the lowest dose at £99 for a month's supply and the highest at £199. When the pill launched in the United States, the manufacturer priced the starting dose at around £110 a month, so UK pricing is in a similar ballpark, though some pharmacies are offering introductory discounts on the first few doses.
The drug works by mimicking a hormone called GLP-1 that the intestine releases after eating. It signals the brain's appetite centres, making people feel fuller and less inclined to eat. In a 64-week trial, people taking the Wegovy tablet alongside a reduced-calorie diet and increased physical activity lost an average of 13.61 per cent of their body weight, compared with 2.18 per cent in the placebo group. The side effects are largely gastrointestinal: nausea, vomiting, constipation, and diarrhoea are very common. Some people experience stomach pain, headaches, or tiredness. Rarely, more serious complications can occur, including low blood sugar, pancreatitis, or severe allergic reactions. The medication is not suitable for anyone under 18, pregnant, or breastfeeding.
One crucial caveat: these drugs are not meant to be short-term fixes or cosmetic interventions. Health experts warn strongly against using them as a quick route to a "beach body," even though misuse clearly happens. The weight often returns once you stop taking the medication. Susan Jebb, a professor of diet and population health at the University of Oxford, notes that while these drugs have potential for long-term use—similar to blood pressure or cholesterol medication—she remains cautious about relying on them as a solution to obesity. The real problem, she suggests, is structural: "Pretty much everybody has a good intention to eat healthily today, but somehow that gets eroded when you walk down the high street and there are coffee shops and cafes and muffins... and chocolates on a three-for-two deal."
The pill received regulatory clearance from the Medicines and Healthcare products Regulatory Agency earlier this month, making it the first tablet of its kind to be approved in the UK. But NHS availability is another matter entirely. That decision rests with the National Institute for Health and Care Excellence, which will review trial data and assess cost-effectiveness before making a recommendation. For now, the pill remains a private option—available to those who can afford it and willing to navigate the strict dosing requirements that come with swallowing rather than injecting.
Notable Quotes
Pretty much everybody has a good intention to eat healthily today, but somehow that gets eroded when you walk down the high street and there are coffee shops and cafes and muffins... and chocolates on a three-for-two deal.— Susan Jebb, Professor of Diet and Population Health, University of Oxford
The Hearth Conversation Another angle on the story
Why does the pill version matter if the injection already exists and works just as well?
Because needles are a genuine barrier for some people. Not everyone can overcome that psychological hurdle, no matter how effective the treatment. The pill removes that obstacle, even if it introduces others.
What are those other obstacles?
The daily ritual. You have to fast for eight hours, take it on an empty stomach with plain water only, then wait 30 minutes before eating. The injection is once a week, any time of day, and you can eat whenever you want. For someone with a chaotic schedule or who travels, that's a real trade-off.
So it's not actually simpler, just different.
Exactly. It trades one kind of friction for another. Some people will find the daily pill easier to remember and less intimidating. Others will find the fasting window and the rigid timing impossible to sustain.
The trial showed 13.61 per cent weight loss. That sounds significant.
It is, compared to placebo. But the source material is careful to note that weight often comes back when you stop the medication. This isn't a cure. It's a tool that only works if you keep using it, ideally alongside actual diet and exercise changes.
Why is the expert worried about relying on these drugs?
Because they address the symptom, not the cause. She's pointing out that the food environment itself—the abundance of cheap, appealing junk food everywhere—is the real problem. A pill can suppress appetite, but it can't change the fact that a muffin is cheaper and more convenient than an apple.
When will people be able to get this on the NHS?
That's still unknown. The regulator approved it, but now it has to go through a cost-effectiveness review. That could take months or longer. For now, it's only available privately, which means it's only accessible to people who can pay.